Indication

CMV retinitis in immunocompromised patient

Cytomegalovirus (CMV) retinitis in an immunocompromised patient is a serious, vision-threatening opportunistic viral infection of the retina caused by the reactivation of latent human cytomegalovirus. Read more about CMV retinitis in immunocompromised patient

10 drugs 10 manufacturers

Advertisement

Drugs that treat it

Common CMV retinitis in immunocompromised patient therapies.

Showing 10–10 of 10 drugs

GANCICLOVIR SODIUM

ANTIVIRAL - CMV INFECTION·PREVENTION OF CMV DISEASE AFTER ORGAN TRANSPLANT·+2
FRESENIUS KABI
Filter & compare in the drug finder →Opens the drug finder with CMV retinitis in immunocompromised patient preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About CMV retinitis in immunocompromised patient.

Cytomegalovirus (CMV) retinitis in an immunocompromised patient is a serious, vision-threatening opportunistic viral infection of the retina caused by the reactivation of latent human cytomegalovirus.

It predominantly affects individuals with profound cell-mediated immunodeficiency, most commonly those with advanced HIV/AIDS and low CD4 counts, as well as organ transplant recipients and patients receiving intensive immunosuppressive therapy.

Pathophysiologically, uncontrolled viral replication causes necrotizing retinitis characterized by full-thickness retinal necrosis, vascular attenuation, and dense intraretinal hemorrhages, often presenting ophthalmoscopically in a granular or fulminant pattern.

Without timely intervention, the infection characteristically leads to progressive visual field defects, irreversible vision loss, and rhegmatogenous retinal detachment.

Personalize your experience

Follow CMV retinitis in immunocompromised patient and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it